OLC and others continue to be ranked, with a Financial Estimates for the operating profit decrease of 7.0% for the fiscal year ending March 2026.
OLC <4661> is ranked (as of 1:32 PM). There was a significant decline. On the 28th, it was announced that the operating profit for the fiscal year ending March 2025 was 172.1 billion yen, up 4.0% compared to the previous period, but for the fiscal year ending March 2026, it is expected to be 160 billion yen, indicating an unexpected decrease in profit guidance of 7.0%. The consensus was believed to be nearly 190 billion yen. In addition to weak visitor plans, the increased burden of upfront investments seems to contribute to the decrease in profit. Volume change rate ranking [as of April 30, 1:32 PM] (recently.
Kandenko, Amano ETC (Additional) Rating
Upgraded - Bullish Code Stock Name Securities Company Previous Change After----------------------------------------------------------------- <4626> Taiyo HD Morgan S "Equal W" "Over W" <8308> Resona HD Nomura "Neutral" "Buy" Target Price Change Code Stock Name Securities Company Previous Change After-------------------------------------
ZETA---Kao's "My Kao Mall" introduces the review, feedback, and Q&A engine "ZETA VOICE."
On the 30th, ZETA <6031> announced that its review, feedback, and Q&A engine "ZETA VOICE" has been introduced to the official online shop "My Kao Mall" operated by Kao <4452>. With this introduction, "ZETA VOICE" is supporting the improvement of UX. The site already features the EC Commodity ETF search and site search engine "ZETA SEARCH," and a recommendation engine."
Stocks hitting the upper and lower limits before the market.
■ Limit up <4240> Cluster Technology <4506> Sumitomo Pharma ■ Limit down <6836> Plat Home *Includes temporary limit up and down (indicative prices).
Sumitomo Pharma --- reached the upper limit of price increase, significantly revised upwards beyond expectations, making an impact.
The stock reached its upper limit. The upward revision of the financial results for the fiscal year ending in March 2025 was announced the day before yesterday. The core operating profit was raised from the previous estimate of 30 billion yen to 43.2 billion yen, while the previous term had a loss of 133 billion yen. In the North America segment, the treatment for advanced prostate cancer "Orgovix" appears to be exceeding expectations. Although impairment losses will be recognized, the operating profit has also been raised from 21 billion yen to 28.8 billion yen, significantly exceeding the market consensus of approximately 15 billion yen.
Japanese Stocks Rise at Open Tracking Wall Street Momentum
Cui Nyonya Kueh : Thank you see you tomorrow !